Inactive Instrument

Lotus Pharmaceuticals, Inc. Stock Other OTC

LTUS

US5457152032

Valuation: Lotus Pharmaceuticals, Inc.

Market Cap	9.74M 8.43M 7.88M 7.2M 13.57M 929M 13.78M 92.38M 36.25M 465M 36.56M 35.76M 1.55B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.45M 11.64M 10.64M 20.04M 1.37B 20.36M 136M 53.55M 686M 54M 52.83M 2.29B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

* Estimated data More valuation ratios

Latest news : Lotus Pharmaceuticals, Inc.

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
21-09-28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
12-05-16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
12-04-19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

More news

Press Releases: Lotus Pharmaceuticals, Inc.

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
25-10-06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
25-08-12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
25-02-21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
24-11-08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

More press releases

Managers and Directors: Lotus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Georgene Rivers CEO	Chief Executive Officer	-	-

Director	Title	Age	Since
Georgene Rivers BRD	Director/Board Member	-	-

More insiders

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LOTUS PHARMACEUTICALS, INC.	+41.51%	-18.92%	-	-	7.93M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.12%	-0.72%	+21.23%	+72.19%	48.92B
OTSUKA HOLDINGS CO., LTD.	-1.14%	+9.22%	+60.80%	+124.81%	41.53B
CIPLA LIMITED	-0.32%	+0.16%	-2.82%	+16.97%	12.43B
ZYDUS LIFESCIENCES LIMITED	+6.43%	+6.16%	+25.54%	+84.28%	11.7B
KRKA, D. D.	-0.48%	-0.38%	+30.98%	+137.44%	9.09B
GEDEON RICHTER	+0.31%	+6.19%	+22.02%	+36.45%	7.4B
ONO PHARMACEUTICAL CO., LTD.	+1.62%	+3.49%	+41.67%	-13.45%	7.15B
GLENMARK PHARMACEUTICALS LIMITED	+1.10%	+2.92%	+11.75%	+185.77%	6.66B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.03%	+8.55%	-24.59%	+30.34%	5.95B
Average	+4.96%	+3,738.35%	+20.73%	+74.98%	16.76B
Weighted average by Cap.	+0.39%	+5,024.32%	+29.84%	+84.55%

	2009	2010
Net sales	57.82M 50.06M 46.79M 42.76M 80.59M 5.51B 81.85M 549M 215M 2.76B 217M 212M 9.19B	72.7M 62.93M 58.82M 53.76M 101M 6.93B 103M 690M 271M 3.47B 273M 267M 11.55B
Net income	16.43M 14.23M 13.3M 12.15M 22.9M 1.57B 23.26M 156M 61.18M 784M 61.7M 60.36M 2.61B	14.42M 12.49M 11.67M 10.67M 20.1M 1.38B 20.42M 137M 53.71M 688M 54.16M 52.98M 2.29B
Net Debt	5.29 4.58 4.28 3.92 7.38 504.89 7.49 50.23 19.71 252.59 19.88 19.44 841.25	4.65 4.02 3.76 3.44 6.48 443.18 6.58 44.09 17.3 221.71 17.45 17.07 738.42

Lotus Pharmaceuticals, Inc. Stock Other OTC

Stocks

LTUS

US5457152032

Pharmaceuticals

Valuation: Lotus Pharmaceuticals, Inc.

Latest news : Lotus Pharmaceuticals, Inc.

Press Releases: Lotus Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Lotus Pharmaceuticals, Inc.

Generic Pharmaceuticals

Financials

Company Profile